Bio News
Twice-yearly TSLP antibody WIN378 to advance into Phase 3 OrbiMed, RA Capital and other biopharma investors participate
Windward Bio has raised 239.2 billion won ($165 million) to advance the long-acting TSLP antibody WIN378 into Phase 3 clinical trials. WIN378 is an asthma treatment administered twice a year, and the company aims to begin the Phase 3 study in the fourth quarter of 2026. With the funding, the company also plans to launch proof-of-concept studies of the bispecific antibody WIN027, accelerating its efforts to target the TSLP inhibitor market.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
